Skip to main content
EUSTAR database study of 17,805 scleroderma (SSc) pts, 468 (2.6%) used HCQ with no effect on or improvement on HAQ-DI, o

Dr. John Cush RheumNow

1 year 6 months ago
EUSTAR database study of 17,805 scleroderma (SSc) pts, 468 (2.6%) used HCQ with no effect on or improvement on HAQ-DI, or hand function scores when comparing HCQ users to non-HCQ users. https://t.co/Tu4tfG74pn https://t.co/Kckx3zTiJ4
Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht

Dr. John Cush RheumNow

1 year 6 months ago
Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/0i5ZMJSxnp https://t.co/zeQ7QhmA0n
Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast.

Dr. John Cush RheumNow

1 year 6 months ago
Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk
Full read review on inflammatory myositis (Patient or med student level knowlegdge) Epidemiology
Risk Factors
Prognosis

Dr. John Cush RheumNow

1 year 6 months ago
Full read review on inflammatory myositis (Patient or med student level knowlegdge) Epidemiology Risk Factors Prognosis Sxs, Dx, Differential Dx Treatment Complications Myositis Guidelines https://t.co/s0LtHyYeuS https://t.co/lMEpMIotSP
Missed RheumNow Live but still want the great coverage? For the first time ever, https://t.co/4UQlqwujiR 2025 is Availab

Dr. John Cush RheumNow

1 year 6 months ago
Missed RheumNow Live but still want the great coverage? For the first time ever, https://t.co/4UQlqwujiR 2025 is Available On Demand! ✔️ STEP Talks from top rheumatologists ✔️ Lectures on the biggest clinical challenges ✔️ Speaker slides and handouts you’ll use Non-CME, https://t.co/lns8EQBZjw
Worse Outcomes in HLA-B27+ JIA

Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marke

Dr. John Cush RheumNow

1 year 6 months ago
Worse Outcomes in HLA-B27+ JIA Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study. https://t.co/VEKqHvO1qw https://t.co/49y0JQL0Gr
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
A randomized, sham-controlled trial has shown that repetitive transcranial magnetic stimulation (rTMS) reduced pain in fibromyalgia for up to 8 weeks; while analgesic effects waned, functional improvements remained during extended maintenance at week 16.
A new study by researchers at Peking University and the Chinese PLA General Hospital has found that multimorbidity—living with multiple chronic diseases—is closely associated with worsening fall conditions and mortality among middle-aged and older adults in China.
Peripheral Nerve Blocks for Hip Fractures

JAMA reviews the use of peripheral nerve block with hip fractures as an effe

Dr. John Cush RheumNow

1 year 6 months ago
Peripheral Nerve Blocks for Hip Fractures JAMA reviews the use of peripheral nerve block with hip fractures as an effective pain management strategy that can be performed by credentialed clinicians outside of the operating room. https://t.co/baeLWVxeUo https://t.co/ZBTVDT0jGR
A comprehensive examination of the pathogenesis and recent advancements in Familial Mediterranean Fever (FMF). This cond

Dr. John Cush RheumNow

1 year 6 months ago
A comprehensive examination of the pathogenesis and recent advancements in Familial Mediterranean Fever (FMF). This condition results from autosomal recessive mutations in the MEFV gene, which codes for Pyrin, a crucial component of the NLRP3 inflammasome. These genetic https://t.co/XNV89LW893
A study in mice shows that JAK inhibition In mice model of status epilepticus (SE) didnt prevent initial SE but when did

Dr. John Cush RheumNow

1 year 6 months ago
A study in mice shows that JAK inhibition In mice model of status epilepticus (SE) didnt prevent initial SE but when did effect chronic phase of Sz weeks after SE induction of SE, suppressing seizures, and epilepsy-associated histopathological alterations. Sz suppression lasted https://t.co/GMIPCtoc7x
ACPA specificity and recognition motifs examined in 6,907 patients with RA from 5 Scandinavian cohorts. ACPA targeting n

ACR_Journals ACR_Journals

1 year 6 months ago
ACPA specificity and recognition motifs examined in 6,907 patients with RA from 5 Scandinavian cohorts. ACPA targeting non-glycine citrulline motifs assoc. more strongly w/ HLA-SE; ACPA to glycine citrulline motifs assoc. w/ smoking and IgA ACPA A&R https://t.co/PmKv3dZLc4 https://t.co/NdPG4Orfj4
Autoimmune Disease Impact Report

Integrated Benefit Institute, a nonprofit independent research organization, has publ

Dr. John Cush RheumNow

1 year 6 months ago
Autoimmune Disease Impact Report Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: https://t.co/TfXZti5NN3
×